Week Ahead: VERA PDUFA July 7; COAG Presentations @ISTH July 11-15

Research evidence excerpt

Week Ahead: VERA PDUFA July 7; COAG Presentations @ISTH July 11-15

USA | Biotechnology EquityJulyResearch6, 2026

Week Ahead: VERA PDUFA July 7; COAG

Presentations @ISTH Jully 11-15

VERA's atacicept IgAN PDUFA is scheduled for July 7th. We expect VERA's

pot'l accel approval to be in-line w/ Voyxact's label w/ no UPCR threshold.

ISTH starts this wk (July 11-July 15): COAG will present HMB-003 preclin data

7/11 and incremental SAD data in Von Willebrand disease (VWD) 7/12; next

wk's ISTH presentations incl Star/INCY's VWD data 7/13 & COAG's Glanzmann

thrombasthenia long-term extension data 7/14.

Medical confs this wk

Intl Society on Thrombosis & Haemostasis (July 11-July 15): see our note on abstracts (here)•

COAG (oral): OC 12.5 First-in-human investigation of HMB-002: a subcutaneous •

antibody for prophylactic management of Von Willebrand disease. July 12, 10:15 AM

- 10:30 AM CEST.

COAG (oral): OC 05.1 A long-acting peptide plasmin inhibitor with extended •

antifibrinolytic activity enabling once-per-cycle subcutaneous treatment for heavy

menstrual bleeding: Preclinical development of HMB-003. July 11, 2026, 1:00 PM - 1:15

PM CEST.

COAG (oral): OC 57.3 Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results •

from a Phase 2 Long-Term Extension. July 14, 10:00 AM - 10:15 AM CEST.

INCY (Star): OC 32.3 Subcutaneous Four-Week Dosing of the Novel Protein S Antibody •

VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients

with Von Willebrand Disease: Phase 1/2 Multi-Dose Study Results. July 13, 10:00 –

10:15 a.m. CEST.

HemA gene-editing poster: PB2040 A Potentially Curative Gene-Editing Approach For •

Hemophilia A Supported by Extensive Preclinical Data in NHP

COAG (oral): OC 12.4 Elucidating Sutacimig’s Dual Mechanism in Factor VII Deficiency: •